“First do no harm”: kidney drug targeting to avoid toxicity in ADPKD
- 1 September 2018
- journal article
- editorial
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 315 (3) , F535-F536
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Defense (DOD) (W81XWH-15-1-0663, W81XWH-15-1-0420)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHBLI) (R00 HL124279)
This publication has 12 references indexed in Scilit:
- Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney diseaseAmerican Journal of Physiology-Renal Physiology, 2018
- Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug deliveryNano Research, 2018
- New treatment paradigms for ADPKD: moving towards precision medicineNature Reviews Nephrology, 2017
- Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials DatabaseDrug Safety, 2015
- Exploitation of the Polymeric Immunoglobulin Receptor for Antibody Targeting to Renal Cyst Lumens in Polycystic Kidney DiseaseJournal of Biological Chemistry, 2015
- Folate-Conjugated Rapamycin Slows Progression of Polycystic Kidney DiseaseJournal of the American Society of Nephrology, 2012
- Macrophages Promote Cyst Growth in Polycystic Kidney DiseaseJournal of the American Society of Nephrology, 2011
- Activating AMP-activated protein kinase (AMPK) slows renal cystogenesisProceedings of the National Academy of Sciences, 2011
- Everolimus in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2010
- Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2010